tiprankstipranks
Advertisement
Advertisement

TSE:RVV Stock Latest News

Revive expands bucillamine program across infectious diseases
The FlyRevive expands bucillamine program across infectious diseases
2d ago
Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses
PremiumCompany Announcements
Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses
2M ago
Revive Therapeutics announces North American patent filings for bucillamine
PremiumThe Fly
Revive Therapeutics announces North American patent filings for bucillamine
2M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
5M ago
Revive Therapeutics provides update on nerve agent countmeasure study
PremiumThe Fly
Revive Therapeutics provides update on nerve agent countmeasure study
5M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany AnnouncementsRevive Therapeutics Updates on Nerve Agent Countermeasure Study
6M ago
Revive Therapeutics says nerve agent countmeasure study ‘remains in progress’
Premium
The Fly
Revive Therapeutics says nerve agent countmeasure study ‘remains in progress’
6M ago
Revive Therapeutics Closes Second Tranche of Private Placement
Premium
Company Announcements
Revive Therapeutics Closes Second Tranche of Private Placement
8M ago
Revive Therapeutics Extends Private Placement to Support Therapeutic Programs
PremiumCompany Announcements
Revive Therapeutics Extends Private Placement to Support Therapeutic Programs
9M ago
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
PremiumCompany Announcements
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
9M ago
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
PremiumCompany Announcements
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
10M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
11M ago
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
PremiumCompany AnnouncementsRevive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
11M ago
Revive Therapeutics nears completion of nerve agent countermeasure study
Premium
The Fly
Revive Therapeutics nears completion of nerve agent countermeasure study
11M ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
Premium
Company Announcements
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
12M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
PremiumCompany Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
1y ago
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
PremiumCompany Announcements
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
1y ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
PremiumThe Fly
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
1y ago
ATAI
CMND
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
PremiumCompany Announcements
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
1y ago
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
PremiumThe FlyRevive Therapeutics to investigate Bucillamine’s potential in cancer treatment
1y ago
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
Premium
Company Announcements
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
1y ago
Revive enters asset purchase agreement for molecular hydrogen program
Premium
The Fly
Revive enters asset purchase agreement for molecular hydrogen program
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >